Lipopolysaccharide

Bragar Eagel & Squire, P.C. Is Investigating Sanmina, JinkoSolar, Bowlero, and Integra and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 22, 2023
P.C, Life, SANM, JKS, Bank statement, Audit committee, Integra, Lipopolysaccharide, GAAP, Report, PAETEC Holding Corp., NYSE, News, JinkoSolar, Audit, Pharmaceutical industry, Clothing, Sanmina Corporation, Bowlero Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Sanmina's stock price fell $3.05 per share, or 5.7%, to close at $50.50 per share on May 12, 2023.
  • On this news, JinkoSolar's stock price fell $3.91 per share, or 8.25%, to close at $43.47 per share on May 9, 2023.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Sanmina, JinkoSolar, Bowlero, and Integra and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 17, 2023
P.C, Life, SANM, Bank statement, Audit committee, Integra, Lipopolysaccharide, GAAP, Report, PAETEC Holding Corp., NYSE, News, JinkoSolar, Cryptocurrency, Audit, Pharmaceutical industry, Clothing, Sanmina Corporation, Bowlero Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • On this news, JinkoSolar's stock price fell $3.91 per share, or 8.25%, to close at $43.47 per share on May 9, 2023.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 11, 2023
P.C, Research report, Muddy Waters, CMA, Comerica, DLocal, Integra, Lipopolysaccharide, Research, Muddy Waters Research, Atrasentan, Kleffman v. Vonage Holdings Corp., American Banker, Department of the Treasury, DLO, News, NYSE, Cryptocurrency, Pharmaceutical industry, Audit, Chinook

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.
  • On this news, Comerica's stock fell $1.40 per share, or 3.59% to close at $37.59 per share on May 30, 2023.

Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, DLocal, and Comerica and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 6, 2023
P.C, Research report, Muddy Waters, CMA, Comerica, DLocal, Integra, Lipopolysaccharide, Research, Muddy Waters Research, Atrasentan, Kleffman v. Vonage Holdings Corp., American Banker, Department of the Treasury, DLO, News, NYSE, Cryptocurrency, Pharmaceutical industry, Audit, Chinook

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.
  • On this news, Comerica's stock fell $1.40 per share, or 3.59% to close at $37.59 per share on May 30, 2023.

Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites

Retrieved on: 
Wednesday, July 5, 2023
Birmingham School of Law, University, State university system, Septic shock, Sepsis, UAB, Patient, Randomized controlled trial, Management, TSX, Mortality, FDA, Lipopolysaccharide, Pharmaceutical industry, Rutgers University

On track to have 25 active trial sites open by the end of September 2023, with 18 current sites and 2 more expected in July.

Key Points: 
  • On track to have 25 active trial sites open by the end of September 2023, with 18 current sites and 2 more expected in July.
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, “We are pleased to add three additional excellent clinical trial sites for Tigris, which is expected to accelerate patient enrollment and enable us to more rapidly reach our 150 total patient target.
  • A strong pace of enrollment now is important as July and August are traditionally slower months for clinical trials.
  • We continue to advance our Tigris trial and remain encouraged by the outlook with preliminary mortality data that continually exceeds our expectations.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Integra LifeSciences (IART) Investors with Substantial Losses and Persons Who May Assist in Firm’s Investigation into Global Recall and Possible Securities Law Violations to Contact Firm’s Attorneys

Retrieved on: 
Monday, July 3, 2023
Person, Good, EPS, Lipopolysaccharide, Hagens Berman, Good manufacturing practice, News, Pharmaceutical industry, Integra

On May 23, 2023, Integra announced that, after an internal investigation, it initiated a global recall of all products manufactured in its Boston, Mass.

Key Points: 
  • On May 23, 2023, Integra announced that, after an internal investigation, it initiated a global recall of all products manufactured in its Boston, Mass.
  • “We’re focused on investors’ losses and whether Integra misled investors about its compliance with worldwide Good Manufacturing Practices,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Integra and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Integra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.

Bragar Eagel & Squire, P.C. Is Investigating Sanmina, JinkoSolar, Bowlero, and Integra and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 1, 2023
P.C, Life, SANM, JKS, Bank statement, Audit committee, Integra, Lipopolysaccharide, GAAP, Report, PAETEC Holding Corp., NYSE, News, JinkoSolar, Audit, Pharmaceutical industry, Clothing, Sanmina Corporation, Bowlero Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Sanmina's stock price fell $3.05 per share, or 5.7%, to close at $50.50 per share on May 12, 2023.
  • On this news, JinkoSolar's stock price fell $3.91 per share, or 8.25%, to close at $43.47 per share on May 9, 2023.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Integra LifeSciences (IART) Investors with Substantial Losses and Persons Who May Assist in Firm’s Investigation into Global Recall and Possible Securities Law Violations to Contact Firm’s Attorneys

Retrieved on: 
Monday, June 26, 2023
Good, Good manufacturing practice, Person, Lipopolysaccharide, Kleffman v. Vonage Holdings Corp., Hagens Berman, SAN, EPS, News, Cryptocurrency, Pharmaceutical industry, Integra

SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ: IART) investors who suffered substantial losses to submit your losses now .
  • On May 23, 2023, Integra announced that, after an internal investigation, it initiated a global recall of all products manufactured in its Boston, Mass.
  • “We’re focused on investors’ losses and whether Integra misled investors about its compliance with worldwide Good Manufacturing Practices,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Integra and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Is Investigating Bowlero, Integra, Chinook, and DLocal and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, June 25, 2023
P.C, Research report, Muddy Waters, DLocal, Integra, Lipopolysaccharide, Research, Muddy Waters Research, Atrasentan, Kleffman v. Vonage Holdings Corp., NYSE, DLO, News, Cryptocurrency, Pharmaceutical industry, Clothing, Audit, Bowlero Corporation, Chinook

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.
  • On this news, DLocal’s share price fell approximately 26% on April 5, 2023, thereby injuring investors further.

Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Retrieved on: 
Tuesday, June 20, 2023
Septic shock, Sepsis, Standard of care, Patient, PMX, Randomized controlled trial, Management, TSX, Knowledge, Mortality, Lipopolysaccharide, Pharmaceutical industry, Nursing

TORONTO, June 20, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.

Key Points: 
  • The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.
  • During the first quarter, the Company implemented a number of business initiatives, as outlined in Spectral’s investor update call on April 6, 2023, that are targeted to enhance and accelerate Tigris enrollment.
  • Management is pleased to report positive progress on the following initiatives:
    11 patients enrolled in the Tigris trial during the second quarter, subsequent to the Company’s investor update call.
  • The enrollment rate experienced over the past ten weeks maintains the target timeline of 90 patients enrolled around the end of 2023.